RECEIVED CENTRAL FAX CENTER

T-487 P.001/003 F-418

Customer No. 28880

AUG 2 2 2005

Confirmation No. 5399

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pacerwork Reduction Act of 1995, no person	ons are required to respond to a col			isplays a valid OMB control number.
	Application Number	10/777,252		
TRANSMITTAL	Filing Date	February 12, 2004		
FORM	First Named Inventor	Jian-Min Fu		
	Art Unit	1626		
the transport to a strong property of the strong printing Strain	Examiner Name	SHAMEEM, GOLAM M.		M.
(to be used for all correspondence after initial filing)	Attorney Docket Number	PC26832		
Total Number of Pages in This Submission 3				
ENCLOSURES (Check all that apply)				
Document(s) Auth	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence of Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Conarks orization to charge the fee approper to deposit account	Address D and any ad	Appeal of Appeal (Appeal (Appe	Enclosure(s) (please (dentify : : : : : : : : : : : : : : : : : : :
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm Name Pfizer Inc.				
Signature Out The Signature				
Printed name Austin W. Zhang				
Date \$/22/05		Reg. No.	48,061	
CERTIFICATE OF TRANSMISSION/MAILING				
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:				
Typed or printed name Cindy Malocha Date August 22, 2005				
Typed or printed name Cindy Malocha			Date	August 22, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and salect option 2.

USPTO Fax No.

571-273-8300

AUG 2 2 2005

PC26832

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: JIAN-MIN FU

EXAMINER: GOLAM M. SHAMEEM

SERIAL NO.: 10/777,252

ART UNIT:

1626

FILED:

FEBRUARY 12, 2004

CONF. NO.:

5399

FOR:

ARYLSULPHONYL SUBSTITUTED-TETRAHYDRO- AND

HEXAHYDRO-CARBAZOLES

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This paper is in response to the Office Communication mailed 07/22/2005, which issues an Election/Restriction requirement. The Office Communication states that "Claims 1-35 are currently pending in the instant application" and has divided claims 1-35 into a total of six groups (I-VI). Applicant's record shows, however, that the pending claims in the application, on the one hand, do not include claims 5-9, 18, 23-26, and 35, which are identified by the Examiner as pending, and, on the other hand, include claims 36-39, which are not addressed in the Office Action. Upon inquiry of the Applicant's attorney regarding the discrepancy, the Examiner, in a telephone message of August 17, 2005, to Applicant's attorney, clarified that there is an inadvertent error in Office Action as to the pending claims, but nonetheless asked Applicant to proceed with a reply. Upon further inquiry of Applicant's attorney regarding claims 36-39, in a telephone message on August 18, 2005, the Examiner told the Applicant's attorney to make his own groupings and make the election according to the groupings, and that the Examiner will examine the claims. Applicant and their attorney greatly appreciate the Examiner's telephone messages and clarifications. However, Applicant believe that claims 36-39 may not be properly restricted from any other pending claims, nor can be

10/777,252

PC26832

properly grouped with some pending claims in the exclusion of others. Accordingly, Applicant is unable to group claims 36-39 separately, with any groups identified by the Examiner, or in any other way. As such, Applicant is unable to respond to the restriction requirement. Accordingly, Applicant respectfully requests that all the pending claims be examined together. Should the Examiner insist on a restriction requirement, Applicant respectfully requests that a new Office Action that addresses all pending claims be issued.

Respectfully submitted,

Dated: \$7/22/05

Austin W. Zhang

Registration No. 48,06

Pfizer Inc.

2800 Plymouth Road Ann Arbor, MI 48105

Telephone: (734) 622-5035 Facsimile: (734) 622-1553